<PAPER>
  <mode2 name="16244358_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Attenuation of BPDE-induced p53 accumulation by TPA is associated with a decrease in stability and phosphorylation of p53 and downregulation of NF&#954;B activation: role of p38 MAP kinase <CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-1">
      <s sid="2">DNA damage caused by benzo[a]pyrene (B[a]P) or other polynuclear hydrocarbons (PAHs) induce p53 protein as a protective measure to eliminate the possibility of mutagenic fixation of the DNA damage.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
      <s sid="3">12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits p53 response induced by B[a]P and other DNA-damaging agents and may cause tumor promotion.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
      <s sid="4">The molecular mechanism of attenuation of B[a]P-induced p53 response by TPA is not known.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
      <s sid="5">We investigated the effect of TPA on p53 response in (&#177;)-anti-benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE)-treated mouse epidermal JB6(P<sup>+</sup>) Cl 41 cells.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
      <s sid="6">BPDE treatment induced p53 accumulation which was attenuated significantly by TPA.<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
      <s sid="7">Cells treated with BPDE and TPA showed increased ratio of Mdm2 to p53 proteins in p53 immunoprecipitate and decreased p53 life span compared to BPDE-treated cells indicating p53 destabilization by TPA.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="8">TPA also inhibited BPDE-induced p53 phosphorylation at serine15.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="9">Activation of both ERKs and p38 MAPK by BPDE and attenuation of BPDE-induced p53 accumulation by U0126 or SB202190, specific inhibitor of MEK1/2 or p38 MAPK, indicate the role of ERKs and p38 MAPK in p53 accumulation.<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
      <s sid="10">Interestingly, TPA potentiated BPDE-induced activation of ERKs whereas p38 MAPK activation was significantly inhibited by TPA, suggesting that inhibition of p38 MAPK is involved in p53 attenuation by TPA.<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
      <s sid="11">Furthermore, SB202190 treatment caused decreased p53 stability and inhibition of phosphorylation of p53 at serine15 in BPDE-treated cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
      <s sid="12">We also observed that TPA or SB202190 attenuated BPDE-induced nuclear factor kappa B (NF&#954;B) activation in JB6 Cl 41 cells harboring NF&#954;B reporter plasmid.<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
      <s sid="13">To our knowledge this is the first report that TPA inhibits chemical carcinogen-induced NF&#954;B activation.<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
      <s sid="14">Interference of TPA with BPDE-induced NF&#954;B activation implicates abrogation of p53 function which has been discussed.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
      <s sid="15">Overall, our data suggest that abrogation of BPDE-induced p53 response and of NF&#954;B activation by TPA is mediated by impairment of the signaling pathway involving p38 MAPK.<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <SEC>
      <TITLE>Introduction</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
        <s sid="16">Many polynuclear aromatic hydrocarbons (PAHs) including benzo[a]pyrene (B[a]P) are well-known carcinogens and a considerable amount of data supports the role of these compounds in the induction of carcinogenesis (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-1">1</xref>,<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-1">2</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
        <s sid="17">The cytochrome P-450-dependent monooxygenase system metabolically activates B[a]P preferentially to (+)-anti-B[a]P-7,8-diol-9,10-epoxide [(+)-anti-BPDE)], a reactive electrophile which binds to cellular DNA predominantly at the N<sup>2</sup> position of deoxyguanosine (dG) and is implicated as the ultimate carcinogenic metabolite of B[a]P (<xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-1">3</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
        <s sid="18">Although B[a]P possesses carcinogenic potential, the tumorigenicity of B[a]P is greatly enhanced by the presence of tumor promoters (<xref class="xref-bibr" href="#ref-4" rid="xref-ref-4-1">4</xref>,<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-1">5</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
        <s sid="19">There is increasing evidence that DNA damage caused by B[a]P or other PAHs induces p53 levels in a number of animal or cell systems (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-1">6</xref>&#8211;<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-1">9</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
        <s sid="20">Inhibition of p53 induction following DNA damage interferes with p53-mediated protective functions, which may lead to carcinogenesis.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3">
        <s sid="21">Attenuation of DNA damage-induced p53 response by tumor promoters involves two fundamental events including inhibition of p53 accumulation and activation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
        <s sid="22">It is observed that DNA damage-induced p53 accumulation is due mainly to an increase in p53 protein stability rather than to an increase in steady-state p53 mRNA levels (<xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-1">10</xref>,<xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-1">11</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
        <s sid="23">Stability and activation of p53 protein are mainly regulated by its interaction with mouse double minute 2 (Mdm2) oncoprotein and post-translational modifications (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-1">12</xref>&#8211;<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-1">16</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
        <s sid="24">In normal, non-stressed cells, p53 has a short half-life of 15&#8211;20 min (<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-1">17</xref>) and is rapidly degraded by ubiquitin-dependent proteolysis (<xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-1">18</xref>,<xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-1">19</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
        <s sid="25">The key mediator of p53 protein stability, Mdm2 protein, binds to the transactivation domain of p53 (amino acids 20&#8211;40) and functions as an E3 ubiquitin ligase, targeting p53 for ubiquitin-mediated proteolysis (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-2">12</xref>,<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-2">13</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
        <s sid="26">The interaction of p53 with Mdm2 depends on the phosphorylation status of both p53 and Mdm2 proteins (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-1">20</xref>,<xref class="xref-bibr" href="#ref-21" rid="xref-ref-21-1">21</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
        <s sid="27">p53 is known to be phosphorylated in vitro or in vivo by several kinases e.g. ATM, ATR, Chk1, Chk2, DNA-PK at several sites within its N- and C-terminal domains (<xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-2">14</xref>&#8211;<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-2">16</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
        <s sid="28">Many of these kinase-mediated modifications are inducible upon DNA damage.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
        <s sid="29">Amongst the multiple modification sites on p53 molecule, it is observed that phosphorylations at Ser15 and Ser20 play an important role in p53 accumulation and function (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-2">20</xref>&#8211;<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-1">23</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
        <s sid="30">It is also observed among other protein kinases that have been shown to phosphorylate p53 include mitogen-activated protein kinases (MAPK) (<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-1">24</xref>&#8211;<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-1">27</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
        <s sid="31">DNA damage is known to activate the MAPK pathway (<xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-1">28</xref>,<xref class="xref-bibr" href="#ref-29" rid="xref-ref-29-1">29</xref>) and the dysregulation of MAPK signaling in human cancer is well documented (<xref class="xref-bibr" href="#ref-30" rid="xref-ref-30-1">30</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="32">Stabilization and activation of p53 in response to DNA damage are known to be mediated by extracellular signal related kinase (ERK) 1 or 2 (<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-2">24</xref>&#8211;<xref class="xref-bibr" href="#ref-26" rid="xref-ref-26-2">26</xref>,<xref class="xref-bibr" href="#ref-31" rid="xref-ref-31-1">31</xref>) and p38 MAPK (<xref class="xref-bibr" href="#ref-26" rid="xref-ref-26-3">26</xref>&#8211;<xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-2">28</xref>,<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-1">32</xref>), which phosphorylate p53 at several sites.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-4">
        <s sid="33">The biological significance of stabilization/activation of p53 through kinase-mediated phosphorylation relates to the transcriptional activating function of p53 which elicits cell cycle arrest and apoptosis (<xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-1">33</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
        <s sid="34">It is well known that p53-dependent cell cycle arrest requires transactivation of p21<sup>Waf1</sup>, which inhibits the cyclin-dependent kinases (CDK) (<xref class="xref-bibr" href="#ref-34" rid="xref-ref-34-1">34</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
        <s sid="35">As candidates to mediate p53-dependent apoptosis, several p53 target genes including Bax and PIG genes have been suggested (<xref class="xref-bibr" href="#ref-35" rid="xref-ref-35-1">35</xref>,<xref class="xref-bibr" href="#ref-36" rid="xref-ref-36-1">36</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
        <s sid="36">Recently it has been observed that the induction of p53 causes activation of nuclear factor kappa B (NF&#954;B) that correlates with the ability of p53 to induce apoptosis (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-1">37</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac23" novelty="None" advantage="None"/></s>
        <s sid="37">Inhibition or loss of NF&#954;B activity abrogated p53-induced apoptosis, indicating that NF&#954;B is essential in p53-mediated cell death.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac24" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-5">
        <s sid="38">Abrogation of DNA damage-induced p53 stabilization/activation associated with the loss of p53 function may lead to tumor promotion.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
        <s sid="39">TPA (12-O-tetradecanoylphorbol-13-acetate) and other tumor promoters are known to inhibit p53 induction in vivo in mouse skin and in vitro in other mammalian cells in response to DNA-damage caused by B[a]P or other DNA damaging agents (<xref class="xref-bibr" href="#ref-38" rid="xref-ref-38-1">38</xref>&#8211;<xref class="xref-bibr" href="#ref-42" rid="xref-ref-42-1">42</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac25" novelty="None" advantage="None"/></s>
        <s sid="40">On the contrary, it was observed that the tumor promoter phorbol ester alone induced p53 transcriptional activity and activation of NF&#954;B (<xref class="xref-bibr" href="#ref-43" rid="xref-ref-43-1">43</xref>&#8211;<xref class="xref-bibr" href="#ref-46" rid="xref-ref-46-1">46</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac26" novelty="None" advantage="None"/></s>
        <s sid="41">Although treatment of cells individually with either B[a]P or TPA causes activation of p53, the attenuating effect of TPA on BPDE-induced p53 response both in vitro and in vivo is very interesting.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac27" novelty="None" advantage="None"/></s>
        <s sid="42">The mechanism of attenuation of B[a]P-induced p53 response by TPA or other tumor promoters has not been studied.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/></s>
        <s sid="43">In this study, we investigated the mechanism of attenuation of (&#177;)-anti-benzo[a]pyvene-7,8-diol-9(BPDE)-induced p53 response by TPA in promotion-sensitive JB6 mouse epidermal cells (Cl 41) which are widely used for studies of the role of signal transduction pathways in tumor promotion (<xref class="xref-bibr" href="#ref-47" rid="xref-ref-47-1">47</xref>&#8211;<xref class="xref-bibr" href="#ref-50" rid="xref-ref-50-1">50</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
        <s sid="44">Here we demonstrate that attenuation of BPDE-induced p53 response by TPA is associated with a decrease in p53 stability and increased binding of Mdm2 with p53, and that TPA mediates this effect by interfering with p38 MAPK not ERKs, with concomitant inhibition of p53 phosphorylation at serine15 residue.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
        <s sid="45">We also showed that TPA severely interferes with BPDE-induced NF&#954;B activation, a downstream target of p53 implicated in the apoptotic function of p53, and that p38 MAPK may have a role in this regard.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
        <s sid="46">To our knowledge this is the first report that TPA, a tumor promoter, inhibits chemical carcinogen-induced NF&#954;B activation.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Materials and methods</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cells and reagents</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
        <s sid="47">Mouse epidermal JB6 Cl 41 (Cl 41) cells were obtained from American Type Culture Collection (ATCC, VA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
        <s sid="48">The Cl 41 cells stably transfected with firefly luciferase reporter gene driven by a minimal NF&#954;B-responsive region was a gift from Dr Nancy Colburn (<xref class="xref-bibr" href="#ref-51" rid="xref-ref-51-1">51</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="49">(&#177;)-anti-BPDE was purchased from the NCI Chemical Carcinogen Reference Standard Repository (Kansas, Missouri); Oncogene Research Product (San Diego, CA); Promega kit (Madison, WI).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="50">Modified Eagle's Medium (MEM), fetal calf serum (FCS), <span class="sc">l</span>-glutamine and trypsin-EDTA were purchased from Invitrogen Life Technologies (CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
        <s sid="51">Recombinant Elk-1 and ATF-2 fusion proteins, U0126 (MEK1/2 inhibitor) and primary antibodies against phospho-ATF-2 (Thr71), phospho-Elk-1 (Ser383), phospho-p53 (Ser15), p44/42 MAPK, phospho-p44/42 MAPK (Thr202/Tyr204), p38 MAPK and phospho-p38 MAPK (Thr180/Tyr182) were purchased from Cell Signaling (MA); monoclonal mouse anti-p53 and anti-Mdm2 (AB-3) antibodies were from Oncogene Rersearch Product (CA); polyclonal rabbit anti-p53 (FL-393) antibody and protein A/G PLUS-agarose were from Santa Cruz (CA); anti-rabbit and anti-mouse IgG conjugated with horseradish peroxidase were obtained from Sigma (MO); and SB202190 was from Calbiochem (CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
        <s sid="52">All other chemicals were of analytical grade.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cell culture</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
        <s sid="53">Cl 41 cells were cultured as monolayers at 37&#176;C in an atmosphere of 5% CO<sub>2</sub> using MEM containing 5% FCS, 2 mM <span class="sc">l</span>-glutamine, 10 mM sodium pyruvate and penicillin/streptomycin (50 &#956;g/ml each).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
        <s sid="54">The cell cultures were checked on a routine basis for Mycoplasma contamination by the Gibco Mycotect.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Cell treatment and preparation of whole cell extract</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-8">
        <s sid="55">The cells in mid-log growth were treated with 1 &#956;M (&#177;)-anti-BPDE (BPDE) dissolved in DMSO (0.05&#8211;00.1% of the culture volume) for 90 min in serum-free medium and further incubated in 5% serum for 16 h (unless mentioned otherwise) in the absence of BPDE.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
        <s sid="56">For treatment with TPA, the cells in mid-log growth were treated with BPDE first for 90 min followed by treatment with 100 nM TPA for 1 h in serum-free medium and then further incubated in 5% serum.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
        <s sid="57">The cells, 16 h after 90 min of BPDE treatment, were washed three times with ice cold PBS, scraped gently and lysed in 100 &#956;l of lysis buffer A consisting of 1% Triton X-100, 50 mM Tris&#8211;HCl (pH 7.5), 150 mM NaCl, 10 mM EDTA, 1 mM sodium &#946;-glycerophosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 10 &#956;g/ml pepstatin, 1 mM phenylmethanesulfonyl fluoride, 5 &#956;g/ml leupeptin and 100 &#956;g/ml aprotinin (Sigma).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
        <s sid="58">The supernatant collected after centrifugation (14 000 r.p.m. for 20 min at 4&#176;C) was either used immediately or flash-frozen in liquid nitrogen and stored at &#8722;86&#176;C for subsequent analyses.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Western blot and immunoprecipitation</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="59">Untreated cells and cells treated with either BPDE alone or BPDE and TPA were lysed in lysis buffer A, 16 h after BPDE treatment as described before, and the protein in the lysate was fractionated by SDS&#8211;PAGE and transferred to Immobilon P filters (Millipore).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
        <s sid="60">The membrane was blocked for 1 h with TBS containing 5% non-fat dry milk, 0.1% Tween 20 and then incubated for 1 h with the respective primary antibodies in TBS containing 5% non-fat dry milk.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
        <s sid="61">The antibodies used were FL-393 (Santa Cruz), Ab-3 (Oncogene Research Product) and anti-phospho-p53 (Ser15) (Cell Signaling) for p53, Mdm2 and p53 phosphorylated at serine15, respectively.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
        <s sid="62">Bound primary antibody was detected by incubating for 1 h with horseradish peroxidase-conjugated secondary antibody.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/></s>
        <s sid="63">The proteins were visualized by enhanced chemiluminescence using Amersham's ECL western blotting detection reagents (Amersham Biosciences, NJ).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="64">The p53 bound Mdm2 protein level was determined by p53 co-immunoprecipitation assay.<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
        <s sid="65">For the co-immunoprecipitation assay cells were lysed in lysis buffer A. Cell extract (300 &#956;g of protein) was incubated with 3 &#956;g of monoclonal mouse anti-p53 antibody overnight at 4&#176;C with gentle rocking and then 20 &#956;l (packed volume) protein A/G plus agarose beads was added with gentle rocking for 4 h at 4&#176;C.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
        <s sid="66">The beads were washed extensively with lysis buffer and the pellet was re-suspended in 20 &#956;l of 2&#215; SDS buffer followed by SDS&#8211;PAGE fractionation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
        <s sid="67">The levels of p53 and Mdm2 proteins in the immunoprecipitates were selectively measured by western immunoblotting using polyclonal rabbit anti-p53 and anti-Mdm2 (Ab-3) antibodies, respectively, and chemiluminiscent detection system.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Phosphorylation and kinase assay of ERKs and p38 MAPK</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="68">To determine the phosphorylation of ERKs and p38 MAPK, cells grown as monolayer (70&#8211;80% confluent) in 100 mm culture dishes were treated either with BPDE (90 min) alone or with BPDE (90 min) first and then with 100 nM TPA (1 h).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
        <s sid="69">Cells were lysed 4 h after BPDE treatment by adding 0.4 ml 1&#215; SDS sample buffer in the dish and were scraped into microfuge tubes followed by brief probe sonication to sheer the DNA.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
        <s sid="70">Phosphorylation of ERKs and p38 MAPK in the respective cell extract was detected by western immunoblotting using specific anti-phospho antibody.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-12">
        <s sid="71">Kinase assays of ERKs and p38 MAPK were carried out as described by others (<xref class="xref-bibr" href="#ref-25" rid="xref-ref-25-3">25</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
        <s sid="72">Briefly, the treated and untreated cells were harvested in 250 &#956;l of lysis buffer.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
        <s sid="73">The cells were disrupted by repeated aspiration through a 21-gauge needle and then centrifuged at 15 000&#215; g for 5 min at 4&#176;C, and then the supernatant was used for immunoprecipitation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
        <s sid="74">The supernatant fraction (300 &#956;g protein) was incubated with 3 &#956;g of specific ERKs or p38 MAPK antibody with gentle rocking at 4&#176;C overnight.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
        <s sid="75">The immunocomplex was captured by adding 50 &#956;l (20 &#956;l packed beads) of washed Protein A/G plus agarose bead slurry by gentle rocking at 4&#176;C for 2 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp27" novelty="None" advantage="None"/></s>
        <s sid="76">The beads were collected by centrifugation and were washed 3 times with 500 &#956;l ice-cold cell lysis buffer and then twice with 500 &#956;l kinase buffer [25 mM Tris&#8211;HCl (pH 7.5), 5 mM beta-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na<sub>3</sub>VO<sub>4</sub> and 10 mM MgCl<sub>2</sub>].<CoreSc1 atype="GSC" type="Exp" conceptID="Exp28" novelty="None" advantage="None"/></s>
        <s sid="77">The kinase reaction was carried out in the presence of 200 &#956;M ATP in 20 &#956;l kinase buffer at 30&#176;C for 30 min using 2 &#956;g of Elk-1 or ATF-2 as substrate for ERKs and p38 MAPK respectively.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp29" novelty="None" advantage="None"/></s>
        <s sid="78">The reaction was terminated by adding 20 &#956;l 3&#215; SDS Sample Buffer and the phosphorylated proteins were detected by immunoblotting using phospho-specific antibody of the enzyme substrate Elk-1 or ATF-2.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp30" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">NF&#954;B activation assay</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-13">
        <s sid="79">JB6(P<sup>+</sup>) Cl 41 cells harboring NF&#954;B-responsive luciferase reporter gene were first selected in 5% serum-containing MEM in presence of 200 &#956;g/ml G418.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp31" novelty="None" advantage="None"/></s>
        <s sid="80">Cells grown at 70&#8211;75% confluence were treated with either BPDE or BPDE followed by TPA and were harvested 16 h after the BPDE treatment.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp32" novelty="None" advantage="None"/></s>
        <s sid="81">Determination of luciferase activity in the respective cell extract was carried out according to Promega protocol.<CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
        <s sid="82">Briefly, the cells were lysed in lysis buffer (supplied in the kit), freeze-thawed and then centrifuged briefly at 14&#8201;000 r.p.m. An aliquot of 20 &#956;l of the supernatant was mixed with 100 &#956;l of the luciferase assay reagent (Promega kit) and the light intensity was measured by a Luminometer with a 2 s measurement delay and 10 s measurement read.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp33" novelty="None" advantage="None"/></s>
        <s sid="83">NF&#954;B activity in the respective cell extract was expressed as light units (LU) per mg protein.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp34" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Protein estimation</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14">
        <s sid="84">Protein content in the cell extract was determined by using BCA reagent according to Pierce protocol.<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Results</TITLE>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Effect of TPA on p53 accumulation and Mdm2 binding to p53 in response to BPDE</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-15">
        <s sid="85">Degradation of p53 is facilitated by binding of Mdm2 to p53 at the N-terminus (amino acids 19&#8211;26) (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-3">12</xref>,<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-3">13</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac28" novelty="None" advantage="None"/></s>
        <s sid="86">In order to assess the effect of BPDE on p53 and p53-bound Mdm2 protein levels, Cl 41 cells were treated with BPDE and the level of p53 in the cell extract was determined by western immunobloting (<xref class="xref-fig" href="#F1" rid="xref-fig-1-1">Figure 1A</xref>).<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
        <s sid="87">The level of p53-bound Mdm2 protein was determined by co-immunoprecipitation with p53 antibody followed by western blotting of the immunoprecipitate using the respective antibodies (<xref class="xref-fig" href="#F1" rid="xref-fig-1-2">Figure 1B</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
        <s sid="88">A dose-dependent (0&#8211;1.0 &#956;M) increase in the induction of p53 protein with BPDE was observed (<xref class="xref-fig" href="#F1" rid="xref-fig-1-3">Figure 1A</xref>, lanes 1, 2 and 4&#8211;6).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
        <s sid="89">The p53-bound Mdm2 protein level also increased in cells treated with 1.0 &#956;M BPDE compared with untreated cells (<xref class="xref-fig" href="#F1" rid="xref-fig-1-4">Figure 1B</xref>, lane 2).<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-17">
        <s sid="90">We examined whether TPA interferes with the BPDE-induced p53 accumulation which may abrogate p53-mediated protective functions in response to DNA damage.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/></s>
        <s sid="91">BPDE-induced p53 accumulation was significantly inhibited (63% inhibition) by TPA treatment (<xref class="xref-fig" href="#F1" rid="xref-fig-1-5">Figure 1A</xref>, lane 3).<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-18">
        <s sid="92">A significantly higher ratio of Mdm2 to p53 proteins (3.2&#8211;1.0) in p53 immunoprecipitate from cells treated with BPDE and TPA compared with the ratio in the p53 immunoprecipitate from cells treated with BPDE alone (0.92&#8211;1.0) was observed (<xref class="xref-fig" href="#F1" rid="xref-fig-1-6">Figure 1B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
        <s sid="93">Alpha Inotech software was used to quantify the protein band density in all western experiments.<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
        <s sid="94">The Mdm2 protein level is under complex regulation in stressed cells.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac29" novelty="None" advantage="None"/></s>
        <s sid="95">p53 protein which trans-activates Mdm2 gene is also known to be downregulated at protein level by Mdm2 through Mdm2-mediated ubiquitination and proteolytic degradation (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-4">12</xref>,<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-4">13</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac30" novelty="None" advantage="None"/></s>
        <s sid="96">We observed that the downregulation of BPDE-induced p53 accumulation by TPA is not associated with downregulation of the p53-bound Mdm2 protein level; rather an increased ratio of Mdm2 to p53 protein was observed in TPA treated cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
        <s sid="97">The data possibly indicate that TPA inhibits BPDE-induced p53 accumulation by promoting Mdm2-mediated destabilization of p53.<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">Interference of TPA with p53 stability</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-19">
        <s sid="98">We studied the effect of TPA on p53 stability in BPDE-treated Cl 41 cells.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
        <s sid="99">The lifetime (stability) of p53 is determined according to the procedure described before (<xref class="xref-bibr" href="#ref-52" rid="xref-ref-52-1">52</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met8" novelty="None" advantage="None"/></s>
        <s sid="100">Cells were treated either with BPDE and then with TPA or with BPDE alone.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp35" novelty="None" advantage="None"/></s>
        <s sid="101">Before harvesting cycloheximide (protein synthesis inhibitor) was added in the medium and the cells were harvested at different time points (0&#8211;1 h) and analyzed for the p53 protein levels by western immunoblotting (<xref class="xref-fig" href="#F2" rid="xref-fig-2-1">Figure 2</xref>).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp36" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Met" conceptID="Met9" novelty="None" advantage="None"/></s>
        <s sid="102">Cells treated with BPDE followed by TPA had significantly less proportion of p53 protein remaining 1 h after cycloheximide treatment (9.3% remaining) compared with cells treated with BPDE alone (57% remaining) (<xref class="xref-fig" href="#F2" rid="xref-fig-2-2">Figure 2</xref>, panels B and A).<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
        <s sid="103">The data suggest that TPA downregulates p53 protein by decreasing its stability.<CoreSc1 atype="GSC" type="Con" conceptID="Con9" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-21">
        <s sid="104">TPA inhibits p38 MAPK and p38 MAPK-inhibition attenuates BPDE-induced p53 accumulation, stabilization and phosphorylation.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac31" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-22">
        <s sid="105">Downregulation of BPDE-induced p53 accumulation by TPA prompted us to examine the involvement of the signaling pathway(s) which mediates the effect of TPA.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
        <s sid="106">We observed that cells treated with U0126, a specific inhibitor of mitogen activated protein kinase kinase (MEK or MAPKK) or SB202190, a specific inhibitor of p38 MAPK caused attenuation of BPDE-induced p53 accumulation (<xref class="xref-fig" href="#F3" rid="xref-fig-3-1">Figure 3A</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
        <s sid="107">SB202190 (2 &#956;M) and U0126 (10 &#956;M) caused 60% and 40% attenuation of BPDE-induced p53 accumulation, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
        <s sid="108">We further examined whether BPDE induces activation of ERKs and p38 MAPK, and whether TPA has an effect on the activation of ERKs and p38 MAPK in BPDE-treated cells.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp3" novelty="None" advantage="None"/></s>
        <s sid="109">BPDE-treated cells showed increased level of phosphorylation of both the ERKs and p38 MAPK which corresponds with the increased activation of both kinases as evidenced by increased phosphorylation of their substrates Elk-1 and ATF-2, respectively (<xref class="xref-fig" href="#F3" rid="xref-fig-3-2">Figure 3B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
        <s sid="110">Interestingly, TPA treatment caused potentiation of BPDE-induced phosphorylation and activation of ERKs whereas BPDE-induced phosphorylation and activation of p38 MAPK were significantly downregulated by TPA (<xref class="xref-fig" href="#F3" rid="xref-fig-3-3">Figure 3B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
        <s sid="111">It is also observed that cells treated with U0126 (10 &#956;M) and SB202190 (2 &#956;M) at concentrations which inhibited p53 accumulation also inhibited BPDE-induced phosphorylation and activation of ERKs and p38 MAPK, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
        <s sid="112">These results indicate that although p53 accumulation (possibly stabilization) in response to BPDE involves activation of ERKs and p38 MAPK, TPA attenuates BPDE-induced p53 accumulation by interfering with p38 MAPK and not with ERKs.<CoreSc1 atype="GSC" type="Con" conceptID="Con10" novelty="None" advantage="None"/></s>
        <s sid="113">We also observed that p53 stability is reduced to a greater extent in cells treated with BPDE and SB202190 (<xref class="xref-fig" href="#F3" rid="xref-fig-3-4">Figure 3C</xref>; lower panel) compared with cells treated with BPDE alone (<xref class="xref-fig" href="#F3" rid="xref-fig-3-5">Figure 3C</xref>; upper panel).<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
        <s sid="114">BPDE-treated cells show a much higher level of p53 1 h after cycloheximide treatment (57% remaining) compared with the cells treated with BPDE and SB202190 (15% remaining).<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-24">
        <s sid="115">Post-translational modifications of p53 regulate its stability and activation (<xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-3">14</xref>&#8211;<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-3">16</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac32" novelty="None" advantage="None"/></s>
        <s sid="116">DNA damage-induced phosphorylation of p53 at Ser15/20 is important for p53 stability and activity (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-3">20</xref>&#8211;<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-2">23</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac33" novelty="None" advantage="None"/></s>
        <s sid="117">We further investigated whether BPDE-induced p53 accumulation is associated with the phosphorylation of p53 at Ser15/20 residues and whether TPA treatment or inhibition of p38 MAPK has any effect on p53 phosphorylation in BPDE-treated cells.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp4" novelty="None" advantage="None"/></s>
        <s sid="118">We determined phspho-(Ser15/20) p53 levels in extracts of treated and untreated cells using phspho-(Ser15/20) p53-specific antibodies and observed that BPDE upregulated Ser15 phosphorylation of p53 (<xref class="xref-fig" href="#F3" rid="xref-fig-3-7">Figure 3D</xref>) but not Ser20 phosphorylation (data not shown).<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
        <s sid="119">TPA or SB202190 caused significant inhibition of BPDE-induced p53 phosphorylation at Ser15 residue (<xref class="xref-fig" href="#F3" rid="xref-fig-3-8">Figure 3D</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
        <s sid="120">Next, we examined whether p53 accumulation and phosphorylation are also induced by proteasomal inhibitor N-Acetyl-Leu-Leu-Nle-CHO (ALLN) (Calbiochem) in order to compare with BPDE-induced p53 accumulation and phosphorylation, and whether TPA can attenuate ALLN-induced p53 accumulation and phosphorylation, if they occurred.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp5" novelty="None" advantage="None"/></s>
        <s sid="121">Treatment of cells with 30 &#956;M ALLN for 16 h induced p53 accumulation but not p53 phosphorylation at Ser15 and, interestingly, TPA did not attenuate ALLN-induced p53 accumulation (<xref class="xref-fig" href="#F3" rid="xref-fig-3-9">Figure 3E</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        <s sid="122">These results suggest that proteasome inhibition-mediated p53 stabilization is different from BPDE-induced p53 stabilization with respect to p53 phosphorylation and inability of TPA to attenuate ALLN-induced p53 accumulation may have implication that p53 phosphorylation at Ser15 has possibly a role in BPDE-induced p53 stabilization which is interfered by TPA.<CoreSc1 atype="GSC" type="Con" conceptID="Con11" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-25">
        <s sid="123">Taken together the above results suggest a possible role of p38 MAPK acting upstream of p53 in a signal transduction pathway initiated by BPDE, and that TPA interferes with this pathway by inhibiting p38 MAPK activity.<CoreSc1 atype="GSC" type="Con" conceptID="Con12" novelty="None" advantage="None"/></s>
      </p>
      <h3 xmlns:xhtml="http://www.w3.org/1999/xhtml">TPA interferes with NF&#954;B activation</h3>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-26">
        <s sid="124">DNA damage-induced p53 response triggers a variety of signaling pathways to elicit protective events like apoptosis and cell cycle arrest (<xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-2">33</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac34" novelty="None" advantage="None"/></s>
        <s sid="125">Since we observed that TPA attenuates p53 response to BPDE, we further investigated which signaling event(s) downstream of p53 is (are) affected by TPA.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj5" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Res" conceptID="Res22" novelty="None" advantage="None"/></s>
        <s sid="126">p53-dependent cell cycle arrest in response to DNA damage is mediated by p21<sup>WAF1</sup> which is a transactivation product of p53 tumor suppressor protein.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac35" novelty="None" advantage="None"/></s>
        <s sid="127">We did not observe any effect of TPA on p21<sup>WAF1</sup> expression in cells treated with BPDE (data not shown).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
        <s sid="128">p53-mediated activation of the transcription factor NF&#954;B is involved in the induction of apoptosis (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-2">37</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac36" novelty="None" advantage="None"/></s>
        <s sid="129">Since NF&#954;B has an important role in the p53-mediated apoptotic signaling event and our data showed that TPA abrogates BPDE-induced p53 response, we were interested in examining whether TPA interferes with NF&#954;B signaling in cells treated with BPDE.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp6" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Mot" conceptID="Mot3" novelty="None" advantage="None"/></s>
        <s sid="130">NF&#954;B activation was determined by NF&#954;B-responsive luciferase reporter assay as described in Materials and methods.<CoreSc1 atype="GSC" type="Met" conceptID="Met10" novelty="None" advantage="None"/></s>
        <s sid="131">BPDE treatment of Cl 41 reporter cells showed a dose- and time-dependent induction of NF&#954;B activity (<xref class="xref-fig" href="#F4" rid="xref-fig-4-1">Figure 4A and B</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/></s>
        <s sid="132">Up to 4 h after BPDE treatment, no significant increase in NF&#954;B activity was observed followed by a gradual increase in NF&#954;B activity with time, reaching the maximum at 16 h (53-fold induction) and remaining at this level up to 24 h (<xref class="xref-fig" href="#F4" rid="xref-fig-4-2">Figure 4A</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res23" novelty="None" advantage="None"/></s>
        <s sid="133">Gradual increase of NF&#954;B activity was also observed with increasing doses of BPDE treatment (<xref class="xref-fig" href="#F4" rid="xref-fig-4-3">Figure 4B</xref>).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/></s>
        <s sid="134">Cells treated with TPA alone also showed increased NF&#954;B activity (3-fold) (<xref class="xref-fig" href="#F4" rid="xref-fig-4-4">Figure 4C</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None"/></s>
        <s sid="135">Most interestingly, TPA caused a marked inhibition (72%) of BPDE-induced NF&#954;B activity instead of the additive activation expected for the combined action of TPA and BPDE (<xref class="xref-fig" href="#F4" rid="xref-fig-4-5">Figure 4C</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res25" novelty="None" advantage="None"/></s>
        <s sid="136">To our knowledge this is the first report that TPA being a tumor promoter inhibits NF&#954;B activation in chemical carcinogen-damaged cells.<CoreSc1 atype="GSC" type="Con" conceptID="Con13" novelty="None" advantage="None"/></s>
        <s sid="137">Since it is observed that TPA inhibits BPDE-induced p38 MAPK activation, we examined whether inhibition of p38 MAPK has an effect on BPDE-induced NF&#954;B activation.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp7" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Mot" conceptID="Mot4" novelty="None" advantage="None"/></s>
        <s sid="138">It is observed that SB202190 treatment caused dose-dependent inhibition of BPDE-induced NF&#954;B activation (<xref class="xref-fig" href="#F4" rid="xref-fig-4-6">Figure 4C</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res26" novelty="None" advantage="None"/></s>
        <s sid="139">Treatment of cells with 1 and 2 &#956;M SB202190 caused 22 and 48% inhibition of BPDE-induced NF&#954;B activation, respectively.<CoreSc1 atype="GSC" type="Res" conceptID="Res27" novelty="None" advantage="None"/></s>
        <s sid="140">These results indicate that downregulation of BPDE-induced NF&#954;B activation by TPA is mediated in part by inhibition of p38 MAPK.<CoreSc1 atype="GSC" type="Con" conceptID="Con14" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Discussion</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-28">
        <s sid="141">In this investigation, we examined the effect of TPA on BPDE-induced p53 response in mouse epidermal cells (JB6 Cl 41) in order to obtain an insight into the mechanism by which TPA, an established tumor promoter, exerts its tumor promoting effect.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Obj" conceptID="Obj6" novelty="None" advantage="None"/></s>
        <s sid="142">The promotion-sensitive JB6 Cl 41 cells represent a suitable cellular model to study the tumor promoting activity of various compounds (<xref class="xref-bibr" href="#ref-51" rid="xref-ref-51-2">51</xref>).<CoreSc1 atype="GSC" type="Obj" conceptID="Obj7" novelty="None" advantage="None"/></s>
        <s sid="143">p53 protein plays a pivotal role as a protective agent in cellular response to various types of genomic damage including chemical carcinogens.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac37" novelty="None" advantage="None"/></s>
        <s sid="144">So, any interference with DNA damage-induced p53 response will be detrimental to normal cellular function and may lead to tumorogenesis.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac38" novelty="None" advantage="None"/></s>
        <s sid="145">A previous study demonstrated that TPA caused downregulation of B[a]P-induced p53 accumulation in mouse skin (<xref class="xref-bibr" href="#ref-39" rid="xref-ref-39-2">39</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac39" novelty="None" advantage="None"/></s>
        <s sid="146">Our present study confirms this finding in the cell culture system indicating that BPDE induces p53 accumulation in a dose-dependent manner in Cl 41 cells and that TPA significantly attenuates BPDE-induced p53 response.<CoreSc1 atype="GSC" type="Con" conceptID="Con15" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-29">
        <s sid="147">The mechanism of attenuation of p53 response by TPA has not been studied.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot5" novelty="None" advantage="None"/></s>
        <s sid="148">Understanding the mechanism(s) by which TPA interferes with the cellular protective response to DNA damage will help gain an insight into the mechanism of tumor promotion and thus develop therapeutic strategy to prevent cancer.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot6" novelty="None" advantage="None"/></s>
        <s sid="149">Our data indicate that destabilization of BPDE-induced p53 at protein level is one of the mechanisms by which TPA attenuates p53 accumulation in response to BPDE.<CoreSc1 atype="GSC" type="Con" conceptID="Con16" novelty="None" advantage="None"/></s>
        <s sid="150">Since Mdm2 binding to p53 protein triggers ubiquitin-mediated proteolysis of p53 (<xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-5">12</xref>,<xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-5">13</xref>), our finding of an increased binding of the oncoprotein Mdm2 with p53 in cells treated with BPDE followed by TPA compared with the cells treated with BPDE alone possibly indicates an increased degradation of p53 protein resulting in the attenuation of p53 stability by TPA.<CoreSc1 atype="GSC" type="Con" conceptID="Con17" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Res" conceptID="Res28" novelty="None" advantage="None"/></s>
        <s sid="151">Stabilization of p53 protein which is negatively regulated by Mdm2 protein and activation of p53 responsible for its downstream functions are under complex regulation in cells under stress.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac40" novelty="None" advantage="None"/></s>
        <s sid="152">The most important of these regulatory events is the post-translational modification by phosphorylation at specific sites.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac41" novelty="None" advantage="None"/></s>
        <s sid="153">Phosphorylation of p53 at serine15 and 20 located at trans-activation domain is critical for stability and activation of p53 (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-4">20</xref>&#8211;<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-3">23</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac42" novelty="None" advantage="None"/></s>
        <s sid="154">It has been demonstrated that mutation of either serine15 or serine20 to alanine prevents the full stabilization and activation of p53 (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-5">20</xref>,<xref class="xref-bibr" href="#ref-22" rid="xref-ref-22-4">22</xref>,<xref class="xref-bibr" href="#ref-23" rid="xref-ref-23-4">23</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac43" novelty="None" advantage="None"/></s>
        <s sid="155">Recent studies have proposed that DNA damage-induced phosphorylation of p53 at Ser15 and/or Ser20 attenuates p53&#8211;Mdm2 interaction (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-6">20</xref>,<xref class="xref-bibr" href="#ref-21" rid="xref-ref-21-5">21</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac44" novelty="None" advantage="None"/></s>
        <s sid="156">We observed that BPDE treatment caused phosphorylation of p53 at serine15 residue but not at serine20 and that TPA inhibits BPDE-induced phosphorylation at serine15 of p53.<CoreSc1 atype="GSC" type="Res" conceptID="Res29" novelty="None" advantage="None"/></s>
        <s sid="157">This suggests that attenuation of p53 accumulation and inhibition of p53 phosphorylation at serine15 are two events associated with TPA effect on cells damaged by BPDE.<CoreSc1 atype="GSC" type="Con" conceptID="Con18" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-30">
        <s sid="158">To understand the regulation of these two events, it is important to identify the kinase(s) which is the upstream regulator of both the BPDE-induced stabilization and phosphorylation of p53.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot7" novelty="None" advantage="None"/></s>
        <s sid="159">Our observation of significant attenuation of BPDE-induced p53 accumulation in cells treated with U0126 (MEK inhibitor) or SB202190 (p38 MAPK inhibitor) indicates the possible role of ERKs and p38 MAPK in p53 accumulation.<CoreSc1 atype="GSC" type="Con" conceptID="Con19" novelty="None" advantage="None"/></s>
        <s sid="160">It has been observed previously that ERKs and p38 MAPK have roles in stabilization and activation of p53 though phosphorylation at several sites (<xref class="xref-bibr" href="#ref-24" rid="xref-ref-24-3">24</xref>&#8211;<xref class="xref-bibr" href="#ref-28" rid="xref-ref-28-3">28</xref>,<xref class="xref-bibr" href="#ref-31" rid="xref-ref-31-2">31</xref>,<xref class="xref-bibr" href="#ref-32" rid="xref-ref-32-2">32</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac45" novelty="None" advantage="None"/></s>
        <s sid="161">Interestingly, our results show that treatment of cells with TPA downregulates BPDE-induced p38 activation whereas ERK activation is potentiated significantly suggesting that inhibition of p38 kinase activity mediates the effect of TPA on cellular p53 response to BPDE.<CoreSc1 atype="GSC" type="Res" conceptID="Res30" novelty="None" advantage="None"/></s>
        <s sid="162">This inference is supported by further observation that SB202190 attenuates not only p53 accumulation but also both the p53 stability and p53 phosphorylation at serine15 in BPDE-treated cells.<CoreSc1 atype="GSC" type="Res" conceptID="Res31" novelty="None" advantage="None"/></s>
        <s sid="163">The question remains regarding the possible mechanism of upregulation of ERKs and downregulation of p38 MAPK by TPA in BPDE-treated cells.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot8" novelty="None" advantage="None"/></s>
        <s sid="164">TPA is an established protein kinase C (PKC) activator and the involvement of PKC in phosphorylation and activation of Raf, MEK and ERKs is well documented (<xref class="xref-bibr" href="#ref-46" rid="xref-ref-46-2">46</xref>,<xref class="xref-bibr" href="#ref-53" rid="xref-ref-53-1">53</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac46" novelty="None" advantage="None"/></s>
        <s sid="165">PKC&#945; is also known to activate MAP kinases including p38 MAPK (<xref class="xref-bibr" href="#ref-54" rid="xref-ref-54-1">54</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac47" novelty="None" advantage="None"/></s>
        <s sid="166">In agreement with these reports, our observation of upregulation of ERKs by TPA possibly indicates a role of PKC.<CoreSc1 atype="GSC" type="Con" conceptID="Con20" novelty="None" advantage="None"/></s>
        <s sid="167">But downregulation of p38 MAPK by TPA in BPDE-treated cells observed by us can not be explained by PKC's involvement as observed by others (<xref class="xref-bibr" href="#ref-54" rid="xref-ref-54-2">54</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res32" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Exp" conceptID="Exp37" novelty="None" advantage="None"/></s>
        <s sid="168">Further studies are needed to decipher the signaling event/s which explains the downregulation of p38 MAPK by TPA in BPDE-treated cells.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot9" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-31">
        <s sid="169">Inhibitory effect of TPA on p53 accumulation, stability and phosphorylation (serine15) indicates abrogation of p53 function.<CoreSc1 atype="GSC" type="Con" conceptID="Con21" novelty="None" advantage="None"/></s>
        <s sid="170">One of the important functions of tumor suppressor p53 is the activation of apoptotic signaling pathway (<xref class="xref-bibr" href="#ref-33" rid="xref-ref-33-3">33</xref>,<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-3">37</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac48" novelty="None" advantage="None"/></s>
        <s sid="171">Induction of DNA damage-induced apoptotic signaling pathway in Cl 41cells is associated with p53 phosphorylation at serine15 (<xref class="xref-bibr" href="#ref-27" rid="xref-ref-27-4">27</xref>,<xref class="xref-bibr" href="#ref-55" rid="xref-ref-55-1">55</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac49" novelty="None" advantage="None"/></s>
        <s sid="172">Regarding the involvement of signaling molecules which mediate the downstream apoptotic function of active p53, it has been reported that induction of p53 causes activation of NF&#954;B that correlates with the ability of p53 to induce apoptosis (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-4">37</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac50" novelty="None" advantage="None"/></s>
        <s sid="173">We observed that BPDE treatment induced NF&#954;B activity several-fold and that TPA treatment caused significant inhibition of BPDE-induced NF&#954;B activation.<CoreSc1 atype="GSC" type="Res" conceptID="Res33" novelty="None" advantage="None"/></s>
        <s sid="174">To our knowledge, this is the first report that the tumor promoter TPA downregulates NF&#954;B activation in response to chemical carcinogen-induced DNA damage.<CoreSc1 atype="GSC" type="Con" conceptID="Con22" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-32">
        <s sid="175">The question arises regarding the significance of downregulation of NF&#954;B activity with respect to the tumor-promoting function of TPA.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj8" novelty="None" advantage="None"/></s>
        <s sid="176">It is known that NF&#954;B has dual roles towards the apoptotic function.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac51" novelty="None" advantage="None"/></s>
        <s sid="177">It is a transcription factor that can protect or contribute to apoptosis (<xref class="xref-bibr" href="#ref-56" rid="xref-ref-56-1">56</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac52" novelty="None" advantage="None"/></s>
        <s sid="178">Although the mechanisms underlying the dual nature of NF&#954;B function is not well understood it is suggested that the p53-independent apoptotic activity of E2F-1 is associated with the inhibition of NF&#954;B activation by death receptors such as the TNFR (<xref class="xref-bibr" href="#ref-57" rid="xref-ref-57-1">57</xref>), whereas p53-dependent apoptosis is associated with NF&#954;B activation (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-5">37</xref>).<CoreSc1 atype="GSC" type="Mot" conceptID="Mot10" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Bac" conceptID="Bac53" novelty="None" advantage="None"/></s>
        <s sid="179">Our observation of the inhibitory effect of TPA on BPDE-induced p53 response and NF&#954;B activation possibly indicates the anti-apoptotic effect of TPA in BPDE-damaged cells, which may eventually lead to the acquisition of tumorogenic potential by initiated cells.<CoreSc1 atype="GSC" type="Con" conceptID="Con23" novelty="None" advantage="None"/></s>
        <s sid="180">Previous investigators reported that activation of ERKs and p38 MAPK is involved in the regulation of NF&#954;B activation (<xref class="xref-bibr" href="#ref-37" rid="xref-ref-37-6">37</xref>,<xref class="xref-bibr" href="#ref-58" rid="xref-ref-58-1">58</xref>,<xref class="xref-bibr" href="#ref-59" rid="xref-ref-59-1">59</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac54" novelty="None" advantage="None"/></s>
        <s sid="181">Our findings indicate that TPA inhibits BPDE-induced NF&#954;B activation by interfering with activation of p38 MAPK and not ERKs.<CoreSc1 atype="GSC" type="Con" conceptID="Con24" novelty="None" advantage="None"/></s>
        <s sid="182">Overall our data suggest that abrogation of chemical carcinogen-induced p53 response and of NF&#954;B activation by TPA is mediated by impairment of the signaling pathway involving p38 MAPK.<CoreSc1 atype="GSC" type="Con" conceptID="Con25" novelty="None" advantage="None"/></s>
        <s sid="183">Further studies are underway to understand the mechanism of inhibition of NF&#954;B activity by TPA in BPDE-damaged cells.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot11" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Acknowledgments</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-33">
        <s sid="184">This work was supported by National Institute of Environmental Health Sciences (NIEHS) Grant R15ES12401 (to J.J.M.).</s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-34">
        <s sid="185">Conflict of Interest Statement: None declared.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>References</TITLE>
    </SEC>
  </BODY>
</PAPER>